Efficacy and Safety of Human Intravenous Immunoglobulin 10% (Panzyga®) in Patients with Primary Immunodeficiency Diseases: a Two-Stage, Multicenter, Prospective, Open-Label Study

被引：0
|
作者：
Michael Borte
Isaac R. Melamed
Grazyna Pulka
Barbara Pyringer
Alan P. Knutsen
Hans D. Ochs
Roger H. Kobayashi
Ai Lan Kobayashi
Sudhir Gupta
Magdalena Strach
William Smits
Anna Pituch-Noworolska
James N. Moy
机构：
[1] Klinikum St. Georg gGmbH,Klinik für Kinder
[2] Hospital St. Georg gGmbH Leipzig, und Jugendmedizin
[3] IMMUNOe Research Center Centennial,Immunodeficiency Centre Leipzig (IDCL)
[4] Uniwersytetu Jagiellońskiego,Klinika Alergologii Collegium Medicum
[5] Octapharma Pharmazeutika Produktionsges.m.b.H,Clinical Research and Development Department
[6] Saint Louis University,Department of Pediatrics
[7] University of Washington and Seattle Children’s Research Institute,Division of Pediatric Allergy/Immunology
[8] UCLA School of Medicine,undefined
[9] University of California,undefined
[10] Jagiellonian University Medical College,undefined
[11] The Allergy and Asthma Center,undefined
[12] University Children Hospital,undefined
[13] Stroger Hospital of Cook County,undefined
来源：
Journal of Clinical Immunology | 2017年 / 37卷
关键词：
Primary immunodeficiency diseases; intravenous immunoglobulin; panzyga®; serious bacterial infections;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：603 / 612
页数：9
相关论文
共 50 条
  • [31] Erratum to: Assessing the safety and efficacy of ruxolitinib in a multicenter, open-label study in Japanese patients with myelofibrosis
    Norio Komatsu
    Keita Kirito
    Kazuya Shimoda
    Takayuki Ishikawa
    Kohshi Ohishi
    Kazuma Ohyashiki
    Naoto Takahashi
    Hikaru Okada
    Taro Amagasaki
    Toshio Yonezu
    Koichi Akashi
    International Journal of Hematology, 2017, 105 : 387 - 387
  • [32] A multicenter, open-label, efficacy, pharmacokinetic, and safety study of adalimumab in Japanese patients with ankylosing spondylitis
    Kobayashi, Shigeto
    Harigai, Masayoshi
    Mozaffarian, Neelufar
    Pangan, Aileen L.
    Sharma, Shringi
    Brown, L. Steven
    Miyasaka, Nobuyuki
    MODERN RHEUMATOLOGY, 2012, 22 (04) : 589 - 597
  • [33] Efficacy and safety of human intravenous immunoglobulin 5% (Ig VENA) in pediatric patients affected by primary immunodeficiency
    Ricci, Silvia
    Lippi, Francesca
    Canessa, Clementina
    Guarnieri, Chiara
    Macchia, Roberta
    Azzari, Chiara
    INTERNATIONAL JOURNAL OF IMMUNOPATHOLOGY AND PHARMACOLOGY, 2020, 34
  • [34] Comment on: “Efficacy and Safety of Intravenous Tenecteplase Bolus in Acute Ischemic Stroke: Results of Two Open-Label, Multicenter Trials”
    Prashant B. Rana
    Nilan T. Jacob
    Tomson Toms
    Shraddha Bhure
    American Journal of Cardiovascular Drugs, 2019, 19 : 219 - 221
  • [35] Comment on: "Efficacy and Safety of Intravenous Tenecteplase Bolus in Acute Ischemic Stroke: Results of Two Open-Label, Multicenter Trials"
    Rana, Prashant B.
    Jacob, Nilan T.
    Toms, Tomson
    Bhure, Shraddha
    AMERICAN JOURNAL OF CARDIOVASCULAR DRUGS, 2019, 19 (02) : 219 - 221
  • [36] A Multicenter, Prospective, Open Label, Historically Controlled Clinical Trial to Evaluate Efficacy and Safety in Primary Immunodeficiency Diseases (PID) Patients of Flebogamma® 5% DIF, the Next Generation of Flebogamma®
    Melvin Berger
    Journal of Clinical Immunology, 2007, 27 : 628 - 633
  • [37] A multicenter, prospective, open label, historically controlled clinical trial to evaluate efficacy and safety in primary immunodeficiency diseases (PID) patients of Flebogamma® 5% DIF, the next generation of Flebogamma®
    Berger, Melvin
    JOURNAL OF CLINICAL IMMUNOLOGY, 2007, 27 (06) : 628 - 633
  • [38] Pharmacokinetics, safety, and efficacy of 20% subcutaneous immunoglobulin (Ig20Gly) administered weekly or every 2 weeks in Japanese patients with primary immunodeficiency diseases: a phase 3, open-label study
    Kanegane, Hirokazu
    Endo, Akifumi
    Okada, Satoshi
    Ohnishi, Hidenori
    Ishimura, Masataka
    Nishikomori, Ryuta
    Imai, Kohsuke
    Nonoyama, Shigeaki
    Muramatsu, Hideki
    Wada, Taizo
    Kuga, Atsushi
    Sakamoto, Ko
    Russo-Schwarzbaum, Sharon
    Chu, Liang-Hui
    McCoy, Barbara
    Li, Zhaoyang
    Yel, Leman
    IMMUNOTHERAPY ADVANCES, 2024, 4 (01):
  • [39] Efficacy of quetiapine in patients with bipolar I and II depression: a multicenter, prospective, open-label, observational study
    Jeong, Jong-Hyun
    Bahk, Won-Myong
    Woo, Young Sup
    Seo, Ho-Jun
    Hong, Seung-Chul
    Jon, Duk-In
    Min, Kyung Joon
    Yoon, Bo-Hyun
    NEUROPSYCHIATRIC DISEASE AND TREATMENT, 2013, 9 : 197 - 204
  • [40] Open-label, multicenter, phase 3 extension study of the safety and efficacy of donepezil in patients with Alzheimer disease
    Doody, RS
    Geldmacher, DS
    Gordon, B
    Perdomo, CA
    Pratt, RD
    ARCHIVES OF NEUROLOGY, 2001, 58 (03) : 427 - 433
12345